FILTER

Refine your search with the following facets to narrow down your results.

5 Current news of Oncothyreon

Oncothyreon initiates Phase 1 trial of PX-866 cancer compound

20-Jun-2008 - Oncothyreon Inc. announced enrollment of the first patient in a Phase 1 trial of PX-866 in patients with advanced solid tumors. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), an important cell survival signaling pathway. "PX-866 is ...

inhibitors oncology pharmacokinetics +1

Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer

16-Jun-2008 - Oncothyreon Inc. announced that the first patient has been treated in a Phase 1b clinical trial of PX-12 in patients with advanced metastatic cancer. PX-12 is a proprietary small molecule inhibitor of thioredoxin, a protein that regulates diverse molecular pathways that contribute to the growth, ...

clinical trials drug resistance inhibitors +1

Oncothyreon to receive milestone payment from Merck KGaA

16-May-2008 - Oncothyreon Inc. announced that it has completed the transfer of certain assays and manufacturing technology related to Stimuvax(R) (BLP25 liposome vaccine) to Merck KGaA of Darmstadt, Germany, triggering a payment to Oncothyreon of $3 million. The payment will be made under the terms of the ...

Germany Merck milestone payments +1

Oncothyreon announces issuance of patent for PX-867

27-Mar-2008 - Oncothyreon Inc. announced that the U.S. Patent and Trademark office has issued a patent for PX-867, a small molecule compound currently in preclinical development. The newly issued patent, U.S. Patent No. 7,335,679, includes claims covering both composition of matter of PX-867 and pharmaceutical ...

autoimmune diseases cardiovascular diseases inhibitors +2

Oncothyreon's PX-478 is effective in preclinical model of human lung cancer

27-Feb-2008 - Oncothyreon Inc. announced the presentation of data demonstrating the effectiveness of PX-478 in a preclinical model of human lung cancer at the 8th Annual Targeted Therapies of the Treatment of Lung Cancer meeting of the International Association for the Study of Lung Cancer in Santa Monica, ...

clinical trials diseases inhibitors +6